Who are Acid Nicotinique's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Extended-release niacin (ERN).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acid-nicotinique.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acid Nicotinique — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acid Nicotinique (Acid Nicotinique) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotinic acid derivative / Lipid-modifying agent. Area: Cardiovascular.

phase 3 Nicotinic acid derivative / Lipid-modifying agent GPR109A (HCA2 receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Acid Nicotinique (Acid Nicotinique) — French Cardiology Society. Nicotinic acid (niacin) reduces triglycerides and LDL cholesterol while raising HDL cholesterol through inhibition of hepatic VLDL production and increased lipolysis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Acid Nicotinique TARGET	Acid Nicotinique	French Cardiology Society	phase 3	Nicotinic acid derivative / Lipid-modifying agent	GPR109A (HCA2 receptor)
Extended-release niacin (ERN)	Extended-release niacin (ERN)	Merck Sharp & Dohme LLC	phase 3	Nicotinic acid derivative / Lipid-modifying agent	GPR109A (hydroxycarboxylic acid receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotinic acid derivative / Lipid-modifying agent class)

French Cardiology Society · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acid Nicotinique — Competitive Intelligence Brief. https://druglandscape.com/ci/acid-nicotinique. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing